Because of a lapse in government funding, the information on this
website may not be up to date, transactions submitted via the
website may not be processed, and the agency may not be able to
respond to inquiries until appropriations are enacted. The NIH
Clinical Center (the research hospital of NIH) is open. For more
details about its operating status, please visit
cc.nih.gov. Updates
regarding government operating status and resumption of normal
operations can be found at
opm.gov.
Antimicrobial cationic peptides with a highly conserved amino terminal cathelin-like domain and a more variable carboxy terminal domain. They are initially synthesized as preproproteins and then cleaved. They are expressed in many tissues of humans and localized to EPITHELIAL CELLS. They kill nonviral pathogens by forming pores in membranes.
Entry Term(s)
ALL-38 Peptide
Antibacterial Peptide LL-37
Antimicrobial Peptide LL-37
Bac4 Protein, Bos taurus
CAP-18
CAP18
CAP18 Lipopolysaccharide-Binding Protein
CATH-1 Protein
Cathelicidin
Cathelicidin 1
Cathelicidin Antimicrobial Peptide
Cathelicidin LL-37
Cathelicidin-1
Cathelin-Like Protein
Cathelin-Related Antimicrobial Peptide
FA-LL-37
K9CATH
LL-37 Antibacterial Peptide
LL-37 Peptide
Myeloid Cathelicidin 1 Protein, Equus caballus
Ropocamptide
eCATH-1
eCATH-1 protein, Equus caballus
hCAP-18
Registry Numbers
0
Related Numbers
143108-26-3
Public MeSH Note
2023; ROPOCAMPTIDE was indexed under ANTIMICROBIAL CATIONIC PEPTIDES 2008-2022
Antimicrobial cationic peptides with a highly conserved amino terminal cathelin-like domain and a more variable carboxy terminal domain. They are initially synthesized as preproproteins and then cleaved. They are expressed in many tissues of humans and localized to EPITHELIAL CELLS. They kill nonviral pathogens by forming pores in membranes.